Long Term Outcomes of Ex Vivo Lung Perfusion: A Single Center 10 Year Experience

2018 ◽  
Vol 37 (4) ◽  
pp. S148-S149
Author(s):  
C. Divithotawela ◽  
M. Cypel ◽  
S. Azad ◽  
L. Singer ◽  
M. Binnie ◽  
...  
JAMA Surgery ◽  
2019 ◽  
Vol 154 (12) ◽  
pp. 1143 ◽  
Author(s):  
Chandima Divithotawela ◽  
Marcelo Cypel ◽  
Tereza Martinu ◽  
Lianne G. Singer ◽  
Matthew Binnie ◽  
...  

2015 ◽  
Vol 63 (S 01) ◽  
Author(s):  
W. Sommer ◽  
M. Avsar ◽  
J. Salman ◽  
C. Kühn ◽  
I. Tudorache ◽  
...  

2015 ◽  
Vol 34 (4) ◽  
pp. S282
Author(s):  
W. Sommer ◽  
J. Salman ◽  
M. Avsar ◽  
T. Siemeni ◽  
K. Jansson ◽  
...  

2014 ◽  
Vol 98 ◽  
pp. 340
Author(s):  
W. Sommer ◽  
M. Avsar ◽  
J. Salman ◽  
K. Jansson ◽  
C. Kuehn ◽  
...  

2019 ◽  
Vol 30 (1) ◽  
pp. 30-32
Author(s):  
João Santos Silva ◽  
Anne Olland ◽  
Gilbert Massard ◽  
Pierre-Emmanuel Falcoz

Abstract A best evidence topic was constructed according to a structured protocol. The question addressed was whether pulmonary grafts from donors deceased from hanging offer the same benefit as grafts from donors deceased from other causes in lung transplantation. Of the 17 papers found, 4 provided the best evidence to answer the question. The authors, date, journal, country of publication, study type, group studied, relevant outcomes and results of these papers are tabulated. One study reported a large cohort of donors and analysed the outcomes by cause of death, reporting no differences in survival. The remaining 3 papers analysed observational studies on the outcomes of lung transplantation using pulmonary grafts from donors deceased from hanging, compared with donors deceased from other causes. No differences in the rates of post-transplantation pulmonary graft dysfunction and long-term overall survival were reported. Although the cohort of donors deceased from hanging is small, we conclude that these donors are an important contribution to the donor pool. Ex vivo lung perfusion may have a role in assessing graft viability in this scenario.


2020 ◽  
Vol 29 (157) ◽  
pp. 190132 ◽  
Author(s):  
Sophie C. van der Mark ◽  
Rogier A.S. Hoek ◽  
Merel E. Hellemons

With an improved median survival of 6.2 years, lung transplantation has become an increasingly acceptable treatment option for end-stage lung disease. Besides survival benefit, improvement of quality of life is achieved in the vast majority of patients. Many developments have taken place in the field of lung transplantation over the past decade. Broadened indication criteria and bridging techniques for patients awaiting lung transplantation have led to increased waiting lists and changes in allocation schemes worldwide. Moreover, the use of previously unacceptable donor lungs for lung transplantation has increased, with donations from donors after cardiac death, donors with increasing age and donors with positive smoking status extending the donor pool substantially. Use of ex vivo lung perfusion further increased the number of lungs suitable for lung transplantation. Nonetheless, the use of these previously unacceptable lungs did not have detrimental effects on survival and long-term graft outcomes, and has decreased waiting list mortality. To further improve long-term outcomes, strategies have been proposed to modify chronic lung allograft dysfunction progression and minimise toxic immunosuppressive effects. This review summarises the developments in clinical lung transplantation over the past decade.


Sign in / Sign up

Export Citation Format

Share Document